Artificial intelligence in assisted reproductive technology: separating the dream from reality.

Journal: Reproductive biomedicine online
PMID:

Abstract

This paper critically reviews the role of artificial intelligence (AI) in assisted reproductive technology (ART), a nascent field that has emerged over the last decade. While AI holds immense promise for enhancing IVF efficiency, standardization, and outcomes, its current trajectory reveals significant challenges. Much of the recent literature presents variations on established methodologies rather than groundbreaking advancements, with many studies lacking clear clinical applications or outcome-driven validations. Moreover, the growing enthusiasm for AI in ART is often accompanied by undue hype that obscures its realistic potential and fosters inflated expectations. Despite these limitations, AI-driven innovations such as advanced image analysis, personalized protocols, and automation of embryology workflows are beginning to show value. Machine learning algorithms and robotics may help address inefficiencies, alleviate staff shortages, and improve decision-making in the IVF laboratory. However, progress is tempered by drawbacks including ethical concerns, limited transparency in AI systems, and regulatory impediments. Data-sharing barriers in our field hinder AI tool development significantly. Energy-intensive computational processes and expanding data centers also raise sustainability concerns, underscoring the need for environmentally responsible development. As the field evolves, it must emphasize rigorous validation, collaborative data frameworks, and alignment with the needs of ART practitioners and patients.

Authors

  • Jacques Cohen
    IVF 2.0 LTD, 1 Liverpool Road, Maghull, Merseyside, UK; ART Institute of Washington, Bethesda Maryland, USA; IVFqc, 1185 Sixth Avenue, New York New York, USA.
  • Giuseppe Silvestri
    UOC Urologia, Ospedale San Luca, Lucca, Italy.
  • Omar Paredes
    IVF 2.0 Ltd, London, UK; Biodigital Innovation Lab, Translational Bioengineering Department, CUCEI, Universidad de Guadalajara, Mexico.
  • Hector E Martin-Alcala
    IVF 2.0 Ltd, London, UK; Biodigital Innovation Laboratory, Department of Translational Bioengineering, Centro Universitario de Ciencias Exactas e IngenierĂ­as, Universidad of Guadalajara, Mexico.
  • Alejandro Chavez-Badiola
    New Hope Fertility Center Mexico, Research and Development, Guadalajara, PC, 44630, Mexico. drchavez-badiola@nhfc.mx.
  • Mina Alikani
    Conceivable Life Sciences, New York, New York, USA; Alpha Scientists in Reproductive Medicine, London, UK.
  • Giles A Palmer
    International IVF Initiative, New York, New York, USA; IVF 2.0 Ltd, London, UK; Institute of Life, IASO Hospital, Athens, Greece.